Spots Global Cancer Trial Database for E3-Hormone Refractory Prostrate Cancer Taxotere Combination
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Official Title: A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
Study ID: NCT00498797
Study Description
Brief Summary: The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Research site, Rio de Janeiro, , Brazil
Research Site, Sao Paulo, , Brazil
Research Site, Hamburg, , Germany
Research Site, Hannover, , Germany
Research Site, Kassel, , Germany
Research Site, Tubingen, , Germany
Research Site, Budapest, , Hungary
Research Site, Bloemfontein, , South Africa
Research Site, Cape Town, , South Africa
Research Site, Umea, , Sweden
Research Site, Uppsala, , Sweden
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
